Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. 1994

M de Haas, and J M Kerst, and C E van der Schoot, and J Calafat, and C E Hack, and J H Nuijens, and D Roos, and R H van Oers, and A E von dem Borne
Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam.

In four healthy volunteers, we analyzed in detail the immediate in vivo effects on circulating neutrophils of subcutaneous administration of 300 micrograms of granulocyte colony-stimulating factor (G-CSF). Neutrophil activation was assessed by measurement of degranulation. Mobilization of secretory vesicles was shown by a decrease in leukocyte alkaline phosphatase content of the circulating neutrophils. Furthermore, shortly postinjection, Fc gamma RIII was found to be upregulated from an intracellular pool that we identified by immunoelectron microscopy as secretory vesicles. Intravascular release of specific granules was shown by increased plasma levels of lactoferrin and by upregulation of the expression of CD66b and CD11b on circulating neutrophils. Moreover, measurement of fourfold elevated plasma levels of elastase, bound to its physiologic inhibitor alpha 1-antitrypsin, indicated mobilization of azurophil granules. However, no expression of CD63, a marker of azurophil granules, was observed on circulating neutrophils. G-CSF--induced mobilization of secretory vesicles and specific granules could be mimicked in whole blood cultures in vitro, in contrast to release of azurophil granules. Therefore, we postulate that the most activated neutrophils leave the circulation, as observed shortly postinjection, and undergo subsequent stimulation in the endothelial microenvironment, resulting in mobilization of azurophil granules. Our data demonstrate that G-CSF should be regarded as a potent immediate activator of neutrophils in vivo.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D010196 Pancreatic Elastase A protease of broad specificity, obtained from dried pancreas. Molecular weight is approximately 25,000. The enzyme breaks down elastin, the specific protein of elastic fibers, and digests other proteins such as fibrin, hemoglobin, and albumin. EC 3.4.21.36. Elastase,Pancreatopeptidase,Elastase I,Pancreatic Elastase I,Elastase I, Pancreatic,Elastase, Pancreatic
D003594 Cytoplasmic Granules Condensed areas of cellular material that may be bounded by a membrane. Cytoplasmic Granule,Granule, Cytoplasmic,Granules, Cytoplasmic
D005260 Female Females
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000469 Alkaline Phosphatase An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.

Related Publications

M de Haas, and J M Kerst, and C E van der Schoot, and J Calafat, and C E Hack, and J H Nuijens, and D Roos, and R H van Oers, and A E von dem Borne
January 1998, Archives of dermatology,
M de Haas, and J M Kerst, and C E van der Schoot, and J Calafat, and C E Hack, and J H Nuijens, and D Roos, and R H van Oers, and A E von dem Borne
June 1996, International journal of hematology,
M de Haas, and J M Kerst, and C E van der Schoot, and J Calafat, and C E Hack, and J H Nuijens, and D Roos, and R H van Oers, and A E von dem Borne
January 2009, Current opinion in hematology,
M de Haas, and J M Kerst, and C E van der Schoot, and J Calafat, and C E Hack, and J H Nuijens, and D Roos, and R H van Oers, and A E von dem Borne
May 1997, Current opinion in hematology,
M de Haas, and J M Kerst, and C E van der Schoot, and J Calafat, and C E Hack, and J H Nuijens, and D Roos, and R H van Oers, and A E von dem Borne
August 1991, Journal of dairy science,
M de Haas, and J M Kerst, and C E van der Schoot, and J Calafat, and C E Hack, and J H Nuijens, and D Roos, and R H van Oers, and A E von dem Borne
January 1998, Acta haematologica,
M de Haas, and J M Kerst, and C E van der Schoot, and J Calafat, and C E Hack, and J H Nuijens, and D Roos, and R H van Oers, and A E von dem Borne
October 1988, Biochemical and biophysical research communications,
M de Haas, and J M Kerst, and C E van der Schoot, and J Calafat, and C E Hack, and J H Nuijens, and D Roos, and R H van Oers, and A E von dem Borne
September 2001, Cytokine,
M de Haas, and J M Kerst, and C E van der Schoot, and J Calafat, and C E Hack, and J H Nuijens, and D Roos, and R H van Oers, and A E von dem Borne
August 1996, Chest,
M de Haas, and J M Kerst, and C E van der Schoot, and J Calafat, and C E Hack, and J H Nuijens, and D Roos, and R H van Oers, and A E von dem Borne
September 1986, Journal of cellular physiology,
Copied contents to your clipboard!